001     147249
005     20240229123022.0
024 7 _ |a 10.1007/s00401-019-02078-w
|2 doi
024 7 _ |a pmid:31563982
|2 pmid
024 7 _ |a 0001-6322
|2 ISSN
024 7 _ |a 1432-0533
|2 ISSN
024 7 _ |a altmetric:67417089
|2 altmetric
037 _ _ |a DKFZ-2019-02372
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Wefers, Annika
|0 P:(DE-He78)32977c5abc127b0373ece54294a41f63
|b 0
|e First author
245 _ _ |a Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course.
260 _ _ |a Heidelberg
|c 2020
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1601378617_28064
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2020 Jan;139(1):193-209#EA:B300#
520 _ _ |a The 'isomorphic subtype of diffuse astrocytoma' was identified histologically in 2004 as a supratentorial, highly differentiated glioma with low cellularity, low proliferation and focal diffuse brain infiltration. Patients typically had seizures since childhood and all were operated on as adults. To define the position of these lesions among brain tumours, we histologically, molecularly and clinically analysed 26 histologically prototypical isomorphic diffuse gliomas. Immunohistochemically, they were GFAP-positive, MAP2-, OLIG2- and CD34-negative, nuclear ATRX-expression was retained and proliferation was low. All 24 cases sequenced were IDH-wildtype. In cluster analyses of DNA methylation data, isomorphic diffuse gliomas formed a group clearly distinct from other glial/glio-neuronal brain tumours and normal hemispheric tissue, most closely related to paediatric MYB/MYBL1-altered diffuse astrocytomas and angiocentric gliomas. Half of the isomorphic diffuse gliomas had copy number alterations of MYBL1 or MYB (13/25, 52%). Gene fusions of MYBL1 or MYB with various gene partners were identified in 11/22 (50%) and were associated with an increased RNA-expression of the respective MYB-family gene. Integrating copy number alterations and available RNA sequencing data, 20/26 (77%) of isomorphic diffuse gliomas demonstrated MYBL1 (54%) or MYB (23%) alterations. Clinically, 89% of patients were seizure-free after surgery and all had a good outcome. In summary, we here define a distinct benign tumour class belonging to the family of MYB/MYBL1-altered gliomas. Isomorphic diffuse glioma occurs both in children and adults, has a concise morphology, frequent MYBL1 and MYB alterations and a specific DNA methylation profile. As an exclusively histological diagnosis may be very challenging and as paediatric MYB/MYBL1-altered diffuse astrocytomas may have the same gene fusions, we consider DNA methylation profiling very helpful for their identification.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Stichel, Damian
|0 P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17
|b 1
700 1 _ |a Schrimpf, Daniel
|0 P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc
|b 2
700 1 _ |a Coras, Roland
|b 3
700 1 _ |a Pages, Mélanie
|b 4
700 1 _ |a Tauziède-Espariat, Arnault
|b 5
700 1 _ |a Varlet, Pascale
|b 6
700 1 _ |a Schwarz, Daniel
|0 P:(DE-He78)a46ef05266eafb5f42c207880f97ebf6
|b 7
700 1 _ |a Söylemezoglu, Figen
|b 8
700 1 _ |a Pohl, Ute
|b 9
700 1 _ |a Pimentel, José
|b 10
700 1 _ |a Meyer, Jochen
|0 P:(DE-He78)b6273c0ba3ae37a4d3d1c6b084797f2e
|b 11
700 1 _ |a Hewer, Ekkehard
|b 12
700 1 _ |a Japp, Anna
|b 13
700 1 _ |a Joshi, Abhijit
|b 14
700 1 _ |a Reuss, David E
|0 P:(DE-HGF)0
|b 15
700 1 _ |a Reinhardt, Annekathrin
|0 P:(DE-He78)856d5c1d0205a79190ed88218ffaf9b2
|b 16
700 1 _ |a Sievers, Philipp
|0 P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6
|b 17
700 1 _ |a Casalini, Maria Belen
|0 P:(DE-He78)1e5010244cbd57412baa2f0e2806a182
|b 18
700 1 _ |a Ebrahimi, Azadeh
|0 P:(DE-He78)c1e6f8388afe92ba3e13be35e7bf54d8
|b 19
700 1 _ |a Huang, Kristin
|0 P:(DE-HGF)0
|b 20
700 1 _ |a Koelsche, Christian
|b 21
700 1 _ |a Low, Hu Liang
|b 22
700 1 _ |a Rebelo, Olinda
|b 23
700 1 _ |a Marnoto, Dina
|b 24
700 1 _ |a Becker, Albert J
|b 25
700 1 _ |a Staszewski, Ori
|b 26
700 1 _ |a Mittelbronn, Michel
|b 27
700 1 _ |a Hasselblatt, Martin
|b 28
700 1 _ |a Schittenhelm, Jens
|b 29
700 1 _ |a Cheesman, Edmund
|b 30
700 1 _ |a de Oliveira, Ricardo Santos
|b 31
700 1 _ |a Queiroz, Rosane Gomes P
|b 32
700 1 _ |a Valera, Elvis Terci
|b 33
700 1 _ |a Hans, Volkmar H
|b 34
700 1 _ |a Korshunov, Andrey
|0 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
|b 35
700 1 _ |a Olar, Adriana
|b 36
700 1 _ |a Ligon, Keith L
|b 37
700 1 _ |a Pfister, Stefan
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 38
700 1 _ |a Jaunmuktane, Zane
|b 39
700 1 _ |a Brandner, Sebastian
|b 40
700 1 _ |a Tatevossian, Ruth G
|b 41
700 1 _ |a Ellison, David W
|b 42
700 1 _ |a Jacques, Thomas S
|b 43
700 1 _ |a Honavar, Mrinalini
|b 44
700 1 _ |a Aronica, Eleonora
|b 45
700 1 _ |a Thom, Maria
|b 46
700 1 _ |a Sahm, Felix
|0 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
|b 47
700 1 _ |a von Deimling, Andreas
|0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
|b 48
700 1 _ |a Jones, David
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 49
700 1 _ |a Blumcke, Ingmar
|b 50
700 1 _ |a Capper, David
|0 P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c
|b 51
773 _ _ |a 10.1007/s00401-019-02078-w
|0 PERI:(DE-600)1458410-4
|n 1
|p 193-209
|t Acta neuropathologica
|v 139
|y 2020
|x 1432-0533
909 C O |p VDB
|o oai:inrepo02.dkfz.de:147249
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)32977c5abc127b0373ece54294a41f63
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)b6273c0ba3ae37a4d3d1c6b084797f2e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)856d5c1d0205a79190ed88218ffaf9b2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 17
|6 P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)1e5010244cbd57412baa2f0e2806a182
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)c1e6f8388afe92ba3e13be35e7bf54d8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 35
|6 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 38
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 47
|6 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 48
|6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 49
|6 P:(DE-He78)551bb92841f634070997aa168d818492
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 51
|6 P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2020
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ACTA NEUROPATHOL : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b ACTA NEUROPATHOL : 2017
920 0 _ |0 I:(DE-He78)B300-20160331
|k B300
|l KKE Neuropathologie
|x 0
920 1 _ |0 I:(DE-He78)B300-20160331
|k B300
|l KKE Neuropathologie
|x 0
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 1
920 1 _ |0 I:(DE-He78)B360-20160331
|k B360
|l Pediatric Glioma
|x 2
920 1 _ |0 I:(DE-He78)BE01-20160331
|k BE01
|l DKTK BE zentral
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B300-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)B360-20160331
980 _ _ |a I:(DE-He78)BE01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21